ClinicalTrials.gg
RecruitingNCT06883617ECLIPSE 1Updated Mar 20, 2025

Neurostimulation for Sleep Disordered Breathing

An interventional study of Neuro stimulator Implant in Sleep Disordered Breathing (SDB) and Sleep Apnea, sponsored by Lunair Medical. Recruiting at 1 site in Paraguay. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.

Sponsored by Lunair Medical · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a first in human study to determine if the Lunair Alpha System is safe and effective for treating moderate to severe sleep disordered breathing.

02

Conditions studied

  • Sleep Disordered Breathing (SDB)
  • Sleep Apnea
03

In context

Sleep Apnea Syndromes

1,084 studies on the registry are indexed under Sleep Apnea Syndromes; 171 are open to participants now.

This study's planned enrollment of 45 is below the median of 60 across 673 interventional studies indexed under Sleep Apnea Syndromes.

Browse Sleep Apnea Syndromes studies →

Lead sponsor

Lunair Medical is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject does not tolerate, not compliant to or have access to alternative Sleep Disordered Breathing treatments
  • Subject has moderate to severe sleep disordered breathing as diagnosed by PSG

Exclusion criteria

Exclusion Criteria:

  • Subject is taking opioids, narcotics, sleep or psychotic medications or supplements that may alter consciousness, the pattern of respiration, sleep architecture, or with known effect on sleep-wake function or alertness.
  • Any reason for which, in the judgment of the investigator, the subject is considered to be a poor study candidate
  • Subject has previous upper respiratory tract (URT) surgery or procedure (e.g., uvula, soft palate or tonsils) within 60 days prior to Screening PSG.
  • Subject has a need for chronic supplemental oxygen therapy for any reason
  • Subject has other sleep disorders or sleep hygiene behaviors that confound functional assessments of sleepiness
  • Subject has severe chronic kidney disease
  • Subject exhibits ongoing misuse of alcohol, tobacco, caffeine, or recreational drugs that would impact either the results of or the participation in a sleep study.
  • Subject conducts work or regular activities requiring vigilance
  • Subject is unwilling or unable to refrain from consumption of alcoholic beverages for 24 hours prior to the start of each PSG study.
  • Subject is unwilling or unable to refrain from sleep disordered breathing treatments or devices
  • Subject has an active systemic infection at time of implant.
  • Subject has clinical evidence of immunodeficiency.
  • Any condition likely to require future MRI or diathermy
  • Subject is pregnant
  • Subject has a severe nasal obstruction that could restrict airflow
  • Subject has any trauma to the upper airway
  • Subject has previous surgical resection, prior or current radiation therapy for cancer or congenital malformations in the larynx, tongue, or throat.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Alpha Lunair System implanted subjects

    Device: Neuro stimulator Implant

Interventions

  • DeviceNeuro stimulator Implant

    Neuro Stimulator for treating sleep disordered breathing

06

What researchers measure

Primary outcomes

  1. Safety Endpoint - assessment of procedure or device related adverse events

    Incidence of adverse events (AEs) related to the Lunair system or procedure

    Time frame: enrollment to 12 months post-implant

Secondary outcomes

  1. Improvement in sleep disordered breathing per sleep study

    Improvement in sleep disordered breathing at 6, 12 and 24 months post implant during an attended sleep study

    Time frame: six months, 12 month and 24 months post implant

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06883617
Lead sponsor
Lunair Medical
Responsible party
Sponsor
First posted
Mar 19, 2025
Start date
Jan 13, 2025
Primary completion
Apr 30, 2026 (estimated)
Completion
Dec 15, 2027 (estimated)
Last update
Mar 20, 2025

Study contacts

Andrea Director of Clinical Operations
Contact
andreas@lunairmedical.com
1-866-675-4430

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion